Jones Financial Companies
IBRX icon

Jones Financial Companies’s ImmunityBio IBRX Stock Holding History

Jones Financial Companies’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$390K Sell
44,791
-5,380
-11% -$40.7K ﹤0.01% 2316
2026
Q1 		$370K Buy
50,171
+43,289
+629% +$296K ﹤0.01% 2178
2025
Q4 		$13.6K Buy
6,882
+4,460
+184% +$10.1K ﹤0.01% 3094
2025
Q3 		$6.15K Buy
2,422
+1,122
+86% +$2.89K ﹤0.01% 3286
2025
Q2 		$3.51K Sell
1,300
-17,086
-93% -$45.9K ﹤0.01% 3263
2025
Q1 		$57.7K Buy
18,386
+12,966
+239% +$39.3K ﹤0.01% 1998
2024
Q4 		$13.9K Buy
5,420
+2,000
+58% +$8.33K ﹤0.01% 2395
2024
Q3 		$13.4K Buy
3,420
+300
+10% +$1.39K ﹤0.01% 2105
2024
Q2 		$19.7K Buy
3,120
+120
+4% +$791 ﹤0.01% 1540
2024
Q1 		$16.1K Buy
+3,000
New +$13.6K ﹤0.01% 949

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jones Financial Companies's IBRX Position: Q2 2026 in Review

Jones Financial Companies reduced its ImmunityBio (IBRX) stake by 11% in Q2 2026, selling an estimated $40.7K and leaving 44,791 shares worth $390K. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

Jones Financial Companies first reported a position in IBRX in Q1 2024 and has held it in 10 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Jones Financial Companies held 44,791 shares of ImmunityBio worth $390K as of Q2 2026.
  • Jones Financial Companies sold 5,380 ImmunityBio shares in Q2 2026, an estimated $40.7K.
  • ImmunityBio made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #2316 holding.
  • Jones Financial Companies first reported a position in ImmunityBio in Q1 2024 and has held it in 10 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.